

# Baveno VII



PROGRAMME

## CONSENSUS WORKSHOP PERSONALIZED CARE IN PORTAL HYPERTENSION

**VIRTUAL**

October 27-30, 2021

PEDIATRIC RESEARCH WORKSHOP

**Primary Prophylaxis of Variceal Hemorrhage, Complexities in the Development  
of Evidence-Based Approaches in Pediatrics**

**October 31, 2021**

[www.baveno7.com](http://www.baveno7.com)

# Baveno VII

CONSENSUS WORKSHOP  
PERSONALIZED CARE IN PORTAL HYPERTENSION

October 27-30, 2021

**VIRTUAL**



## BAVENO COOPERATION STEERING COMMITTEE

### HONORARY PRESIDENT

Roberto de Franchis, *Milan (Italy)*

### CHAIR

Jaime Bosch, *Bern (Switzerland)*

### VICE-CHAIR

Guadalupe Garcia-Tsao, *New Haven (USA)*

Juan G. Abraldes, *Edmonton (Canada)*

Agustin Albillos, *Madrid (Spain)*

Annalisa Berzigotti, *Bern (Switzerland)*

Gennaro D'Amico, *Palermo (Italy)*

Andrea De Gottardi, *Lugano (Switzerland)*

Alessandra Dell'Era, *Milan (Italy)*

Juan Carlos Garcia-Pagàn, *Barcelona (Spain)*

Joan Genescà, *Barcelona (Spain)*

Aleksander Krag, *Odense (Denmark)*

Wim Laleman, *Leuven (Belgium)*

Vincenzo La Mura, *Milan (Italy)*

Dominique Thabut, *Paris (France)*

Jonel Trebicka, *Frankfurt (Germany)*

Emmanouil Tsochatzis, *London (UK)*

Dominique Valla, *Paris (France)*

Candid Villanueva, *Barcelona (Spain)*

### SCIENTIFIC SECRETARIES

Thomas Reiberger, *Vienna (Austria)*

Cristina Ripoll, *Jena (Germany)*

# Baveno VII

CONSENSUS WORKSHOP  
PERSONALIZED CARE IN PORTAL HYPERTENSION

October 27-30, 2021



The Baveno Cooperation is an official EASL Research Consortium

## SUPPORTED BY



## ENDORSED BY



# Baveno VII

CONSENSUS WORKSHOP  
PERSONALIZED CARE IN PORTAL HYPERTENSION

October 27-30, 2021

VIRTUAL



## FACULTY

Juan G. Abraldes - *Edmonton, Canada*  
Agustin Albillos - *Madrid, Spain*  
Anna Baiges - *Barcelona, Spain*  
Jasmohan Bajaj - *Richmond, USA*  
Rafael Bañares - *Madrid, Spain*  
Marta Barrufet - *Barcelona, Spain*  
Lina Benajiba - *Paris, France*  
Annalisa Berzigotti - *Bern, Switzerland*  
Jaime Bosch - *Bern, Switzerland*  
Christophe Bureau - *Toulouse, France*  
Vincenza Calvaruso - *Palermo, Italy*  
Andrés Cárdenas - *Barcelona, Spain*  
Gennaro D'Amico - *Palermo, Italy*  
Roberto de Franchis - *Milan, Italy*  
Andrea De Gottardi - *Lugano, Switzerland*  
Alessandra Dell'Era - *Milan, Italy*  
Angels Escorsell - *Barcelona, Spain*  
Jonathan Fallowfield - *Edinburgh, United Kingdom*  
Hector Ferral - *Evanston, USA*  
Sven Francque - *Antwerp, Belgium*  
Ron Gaba - *Chicago, USA*  
Juan Carlos Garcia Pagàn - *Barcelona, Spain*  
Guadalupe Garcia-Tsao - *New Haven, USA*  
Joan Genescà - *Barcelona, Spain*  
Susana Gomes Rodrigues - *Bern, Switzerland*  
Jordi Gracia - *Barcelona, Spain*  
Guohong Han - *Xi'an, China*  
Virginia Hernandez-Gea - *Barcelona, Spain*  
Jidong Jia - *Beijing, China*  
Jean Jacques Kiladjian - *Paris, France*  
Aleksander Krag - *Odense, Denmark*  
Vincenzo La Mura - *Milan, Italy*  
Wim Laleman - *Leuven, Belgium*

# Baveno VII

CONSENSUS WORKSHOP  
PERSONALIZED CARE IN PORTAL HYPERTENSION

October 27-30, 2021

VIRTUAL



## FACULTY

Sabela Lens - *Barcelona, Spain*  
Xuefeng Luo - *Chengdu, China*  
Mattias Mandorfer - *Vienna, Austria*  
Sarwa Darwish Murad - *Rotterdam, The Netherlands*  
Valerie Paradis - *Clichy, France*  
David Patch - *London, United Kingdom*  
Salvatore Piano - *Padua, Italy*  
Massimo Pinzani - *London, United Kingdom*  
Aurelie Plessier - *Clichy, France*  
Massimo Primignani - *Milan, Italy*  
Bogdan Procopet - *Cluj-Napoca, Romania*  
Pierre Emmanuel Rautou - *Paris, France*  
Thomas Reiberger - *Vienna, Austria*  
Cristina Ripoll - *Jena, Germany*  
Marika Rudler - *Paris, France*  
Shiv K. Sarin - *New Delhi, India*  
Filippo Schepis - *Modena, Italy*  
Marco Senzolo - *Padua, Italy*  
Vijay Shah - *Rochester, USA*  
Akash Shukla - *Mumbai, India*  
Puneeta Tandon - *Edmonton, Canada*  
Luis Tellez - *Madrid, Spain*  
Dominique Thabut - *Paris, France*  
Maja Thiele - *Odense, Denmark*  
Jonel Trebicka - *Frankfurt, Germany*  
Dhiraj Tripathi - *Birmingham, United Kingdom*  
Emmanouil A. Tsochatzis - *London, United Kingdom*  
Laura Turco - *Bologna, Italy*  
Fanny Turon - *Barcelona, Spain*  
Dominique Valla - *Clichy, France*  
Candid Villanueva - *Barcelona, Spain*  
Ian Wanless - *Halifax, Canada*  
Hitoshi Yoshiji - *Kashihara, Japan*

# Baveno VII

CONSENSUS WORKSHOP  
PERSONALIZED CARE IN PORTAL HYPERTENSION

October 27-30, 2021

VIRTUAL



## HONORARY FACULTY

**Flemming Bendtsen** - *Hvidovre (Denmark)*

**Norman Grace** - *Boston (USA)*

**Loren Laine** - *New Haven (USA)*

**Didier Lebrec** - *Clichy (France)*

**Carlo Merkel** - *Padua (Italy)*

**Manuela Merli** - *Rome (Italy)*

**Richard Moreau** - *Clichy (France)*

**Frederik Nevens** - *Leuven (Belgium)*

**Markus Peck-Radosavljevic** - *Klagenfurt (Austria)*

**Francesco Salerno** - *Milan (Italy)*

**Tilman Sauerbruch** - *Bonn (Germany)*

**Benjamin Shneider** - *Houston (USA)*

**Jean Pierre Vinel** - *Toulouse (France)*

**Julio Vorobioff** - *Rosario (Argentina)*

# Baveno VII

CONSENSUS WORKSHOP  
PERSONALIZED CARE IN PORTAL HYPERTENSION

October 27-30, 2021

**VIRTUAL**



## WELCOME ADDRESS

Baveno VII is a sequel of the Baveno I-VI Workshops, which were held every 5 years from 1990 to 2015. All the previous Workshops were successful, as proven by more than 4000 citations of the Workshop reports in the medical literature.

After Baveno VI, important advances have been made in understanding the pathophysiology of portal hypertension, as well as in developing new treatments and new strategies for the management of advanced cirrhosis and portal hypertension. For these reasons, we thought that the time had come to organize a seventh Baveno Workshop.

Baveno VII was planned for March 2020 and had to be cancelled a few weeks before the meeting was to be held. At that point in time, we had no sense how the pandemic would develop, and we first decided to postpone the meeting to October 2020. By the summer, the Executive Committee realized that this option was not realistic and had to postpone again to October 2021. Finally, due to the persisting uncertainties, the Executive Committee has recently decided to cancel the face-to-face meeting. Therefore, Baveno VII will be a complete virtual meeting to be held over 4 days (27<sup>th</sup> to 30<sup>th</sup> October). The meeting will be held over 4 to 4h30 per day, starting at 14h00 European time.

As for the previous editions, the aim of the Baveno VII Workshop is twofold: first, to review and put into perspective the changes in diagnostic and therapeutic strategies that have occurred in the past 5 years in the field of portal hypertension, Second, to continue the effort - which had begun in Baveno I more than thirty years ago - of producing updated definitions and guidelines aimed at improving the management of patients as well as the quality of our future studies. The Workshop will begin with a brief introduction, followed by three lectures, the first one on the new concept of risk stratification, the second one on clinical stages and ordinal outcomes in portal hypertension, and the third on lifestyle and genetic modifiers of progression of compensated advanced chronic liver disease.

# Baveno VII

CONSENSUS WORKSHOP  
PERSONALIZED CARE IN PORTAL HYPERTENSION

October 27-30, 2021

VIRTUAL



## WELCOME ADDRESS

The structure of the Workshop is similar to that of the previous ones - there will be 4 sessions: each divided into 2-3 parts. The first session will concern the evaluation and risk stratification of patients with cirrhosis, focusing on the HVPG as a gold standard and on non-invasive surrogates for the diagnosis of compensated advanced chronic liver disease, clinically significant portal hypertension and varices. The second session, dedicated to the new clinical scenarios will be divided into three parts. The first one will include four introductory lectures on progression and regression of cirrhosis; the second one will analyze the impact of etiological therapy for cirrhosis, and the third one will deal with the impact of non-etiological novel therapies in cirrhosis. The third session will deal with the different clinical settings and will also be divided into three parts: the first one will be devoted to the prevention of (first) decompensation, the second one to acute variceal hemorrhage, and the third one to the prevention of further decompensation. The fourth session will be devoted to vascular liver diseases in cirrhosis and will consist of two parts: the first one on diagnosis and staging, and the second one on treatment. According to the Baveno tradition, at the end of each session, updated consensus statements on the topic of the session will be presented and discussed by the Panels and the Audience.



Roberto de Franchis

*On behalf of the Baveno Cooperation Steering Committee*



# Baveno VII

CONSENSUS WORKSHOP  
PERSONALIZED CARE IN PORTAL HYPERTENSION

October 27-30, 2021

**VIRTUAL**



## SCIENTIFIC PROGRAMME

All times are CET

## WEDNESDAY OCTOBER 27 2021

**14.00-14.30** Welcome and introduction  
R. de Franchis (*Milan, Italy*)

### Tribute to the Baveno Legends

Tom Boyer

G. Garcia-Tsao (*New Haven, USA*)

Andrew Burroughs

D. Patch (*London, United Kingdom*)

Roberto Groszmann

J. Bosch (*Bern, Switzerland*)

Luigi Pagliaro

G. D'Amico (*Palermo, Italy*)

### 14.30-15.15 INTRODUCTORY LECTURES

Chairpersons: J. Bosch (*Bern, Switzerland*), R. de Franchis (*Milan, Italy*),  
G. Garcia-Tsao (*New Haven, USA*)

**14.30 LECTURE-1:** New concept of risk stratification  
J.G. Abraldes (*Edmonton, Canada*)

**14.45 LECTURE-2:** Clinical stages and ordinal outcomes in portal hypertension  
G. D'Amico (*Palermo, Italy*)

**15.00 LECTURE-3:** Lifestyle and genetic modifiers of liver disease progression  
A. Berzigotti (*Bern, Switzerland*)

**15.15-15.30** Break



## SCIENTIFIC PROGRAMME

### WEDNESDAY OCTOBER 27 2021

#### 15.30-18.30 SESSION 1

### EVALUATION AND RISK STRATIFICATION

#### 15.30-16.15 PART 1: HVPG as a gold standard

*Chairpersons: J.C. Garcia-Pagà (Barcelona, Spain), H. Ferral (Evanston, USA)*

*Panelists: R. Gaba (Chicago, USA), H. Ferral (Evanston, USA), F. Schepis (Modena, Italy)*

#### 15.30 Quality Metrics in HVPG and Porto-Systemic Pressure Gradient (PPG)

*H. Ferral (Evanston, USA)*

#### 15.37 Usefulness of HVPG in:

- a. the diagnosis of CSPH in cirrhosis of different etiologies
- b. assessing the response to vasoactive drugs for risk stratification of variceal (re-)bleeding
- c. assessing the prognosis of patients with cirrhosis
- d. clinical trials vs. proof-of-concept studies

*F. Schepis (Modena, Italy)*

#### 15.50 PPG in the setting of TIPS

*R. Gaba (Chicago, USA)*

#### 15.55 Proposed consensus statements

*J.C. Garcia-Pagà (Barcelona, Spain), H. Ferral (Evanston, USA)*

#### 16.05 Discussion

#### 16.15-16.30 Break

# Baveno VII

CONSENSUS WORKSHOP  
PERSONALIZED CARE IN PORTAL HYPERTENSION

October 27-30, 2021

VIRTUAL



## SCIENTIFIC PROGRAMME

### WEDNESDAY OCTOBER 27 2021

#### 16.30-18.30 **PART 2: Noninvasive tools for cACLD and portal hypertension**

*Chairpersons: A. Berzigotti (Bern, Switzerland), J. Genescà (Barcelona, Spain)*

*Panelists: J.G. Abraldes (Edmonton, Canada), J. Fallowfield (Edinburgh, United Kingdom), M. Thiele (Odense, Denmark)*

#### 16.30 Introduction

*J. Genescà (Barcelona, Spain), A. Berzigotti (Bern, Switzerland)*

#### 16.35 Compensated Advanced Chronic Liver Disease (cACLD)

*J. Genescà (Barcelona, Spain)*

#### 16.50 Use of noninvasive tools for prognosis in cirrhosis

*M. Thiele (Odense, Denmark)*

#### 17.10 CSPH

*J. Genescà (Barcelona, Spain)*

#### 17.25 Screening for varices and the impact of the Baveno VI criteria

*J.G. Abraldes (Edmonton, Canada)*

#### 17.40 Spleen stiffness

*A. Berzigotti (Bern, Switzerland)*

#### 17.55 Emerging non-invasive markers

*J. Fallowfield (Edinburgh, United Kingdom)*

#### 18.10 Proposed consensus statements

*A. Berzigotti (Bern, Switzerland), J. Genescà (Barcelona, Spain)*

#### 18.25 Discussion

End of the Day

# Baveno VII

CONSENSUS WORKSHOP  
PERSONALIZED CARE IN PORTAL HYPERTENSION

October 27-30, 2021

VIRTUAL



## SCIENTIFIC PROGRAMME

### THURSDAY OCTOBER 28 2021

#### 14.00-14.30 Presentation of selected abstracts

- Test- retest reliability of hepatic venous pressure gradient (HPVG): a study in 289 patients from the placebo group from 20 rct's  
W. Bai
- Incidence, predictors and outcomes of de novo non neoplastic portal vein thrombosis in HBD and HCV cirrhotics treated with antivirals  
G. Tosetti
- Liver stiffness after DAA predicts outcome of HCV patients with compensated advanced chronic liver disease who achieved sustained virological response  
C. Rigamonti

#### 14.30-17.30 SESSION 2

### NEW SCENARIOS

#### 14.30-15.15 PART 1: Progression and regression of cirrhosis

Chairpersons: W. Laleman (*Leuven*), D. Patch (*London*)

- 14.30 **LECTURE-4:** PELS in progression. Can they regress?  
I. Wanless (*Halifax*)
- 14.45 **LECTURE-5:** Fibrogenesis and regression of fibrosis  
M. Pinzani (*London*)
- 15.00 **LECTURE-6:** Angiogenesis and progression of ACLD  
V. Shah (*Rochester*)
- 15.15 *Break*
- 15.30 **LECTURE-7:** Drugs to modify liver fibrosis progression and regression (preclinical and clinical studies)  
J. Gracia (*Barcelona*)



## SCIENTIFIC PROGRAMME

### THURSDAY OCTOBER 28 2021

#### 15.45-16.30 **PART 2: Impact of etiological therapies in the course of cirrhosis**

*Chairpersons: M. Mandorfer (Vienna, Austria), E. Tsochatzis (London, United Kingdom)*

*Panelists: S. Francque (Antwerp, Belgium), J. Jia (Beijing, China), S. Lens (Barcelona, Spain), H. Yoshiji (Kashihara, Japan)*

#### 15.45 Introduction

*M. Mandorfer (Vienna, Austria)*

#### 15.46 Alcohol-related liver disease

*H. Yoshiji (Kashihara, Japan)*

#### 15.54 Non-alcoholic fatty liver disease

*S. Francque (Antwerp, Belgium)*

#### 16.02 Hepatitis B with meta-analysis

*J. Jia (Beijing, China)*

#### 16.10 Hepatitis C

*S. Lens (Barcelona, Spain)*

#### 16.15 Individual patient data meta-analysis for hepatitis C

*M. Mandorfer (Vienna, Austria)*

#### 16.20 Presentation of recommendations for the management of ACLD after removal/suppression of the primary etiological factor

*E. Tsochatzis (London, United Kingdom)*

#### 16.25 Discussion

*M. Mandorfer (Vienna, Austria), E. Tsochatzis (London, United Kingdom)*

#### 16.30-16.45 *Break*

# Baveno VII

CONSENSUS WORKSHOP  
PERSONALIZED CARE IN PORTAL HYPERTENSION

October 27-30, 2021

**VIRTUAL**



## SCIENTIFIC PROGRAMME

### THURSDAY OCTOBER 28 2021

- 16.45-17.30 PART 3: Impact of non-etiological therapies in the course of cirrhosis**  
*Chairpersons: A. Albillos (Madrid, Spain), J. Trebicka (Frankfurt, Germany)*  
*Panelists: J. Bajaj (Richmond, USA), J. Gracia (Barcelona, Spain), A. Krag (Odense, Denmark), W. Laleman (Leuven, Belgium), V. Shah (Rochester, USA)*
- 16.45** Gut liver axis: backbone of cirrhosis progression, pathophysiological basis  
*J. Bajaj (Richmond, USA)*
- 16.55** Future developments: biomarkers  
*A. Krag (Odense, Denmark)*
- 17.05** Future developments: disease modifiers  
*W. Laleman (Leuven, Belgium)*
- 17.15** Proposed consensus statements  
*A. Albillos (Madrid, Spain), J. Trebicka (Frankfurt, Germany)*
- 17.25** Discussion
- 17.30-17.45** *Break*

# Baveno VII

CONSENSUS WORKSHOP  
PERSONALIZED CARE IN PORTAL HYPERTENSION

October 27-30, 2021

VIRTUAL



## SCIENTIFIC PROGRAMME

### THURSDAY OCTOBER 28 2021

17.45-19.00 **SESSION 3**

#### CLINICAL SETTINGS

17.45-19.00 **PART 1: Preventing (first) decompensation.**

##### Review of current evidence

*Chairpersons: J. Bosch (Bern, Switzerland), C. Ripoll (Halle, Germany)*

*Panelists: R. Bañares (Madrid, Spain), V. Calvaruso (Palermo, Italy),*

*A. Dell'Era (Milan, Italy), S. Gomes Rodrigues (Bern, Switzerland),*

*D. Tripathi (Birmingham, United Kingdom), C. Villanueva (Barcelona, Spain)*

**17.45** Results of the questionnaire

*V. Calvaruso (Palermo, Italy)*

**17.50** Definition of decompensation

*C. Ripoll (Halle, Germany)*

**18.00** The role of jaundice, perihepatic ascites, MHE and bleeding due to portal hypertensive gastropathy in the definition of decompensation

*R. Bañares (Madrid, Spain), A. Dell'Era (Milan, Italy)*

**18.08** Impact of the sole presence of infection and of sarcopenia (without other manifestations of decompensation) in the natural history of compensated cirrhosis

*S. Gomes Rodrigues (Bern, Switzerland)*

# Baveno VII

CONSENSUS WORKSHOP  
PERSONALIZED CARE IN PORTAL HYPERTENSION

October 27-30, 2021

VIRTUAL



## SCIENTIFIC PROGRAMME

### THURSDAY OCTOBER 28 2021

- 18.17** Meta-analysis with individual data regarding beta-blockers to prevent first decompensation including all studies that have evaluated “early” prevention  
C. Villanueva (*Barcelona, Spain*)
- 18.27** Specific evaluation of the effect of CSPH, reduction of HVPG and other predictive factors  
D. Tripathi (*Birmingham, United Kingdom*)
- 18.36** Proposed Consensus Statements: Prevention of first decompensation  
J. Bosch (*Bern, Switzerland*)
- 18.55** Discussion

End of the Day



# Baveno VII

CONSENSUS WORKSHOP  
PERSONALIZED CARE IN PORTAL HYPERTENSION

October 27-30, 2021

**VIRTUAL**



## SCIENTIFIC PROGRAMME

### FRIDAY OCTOBER 29 2021

#### 14.00-14.30 Presentation of selected abstracts

- Rifaximin alleviates endotoxemia and intestinal hyperpermeability with partially modified fecal microbiota in cirrhotic patients  
K. Kaji
- Prognosis of patients undergoing salvage TIPS for refractory variceal bleeding is still poor in the preemptive TIPS era  
C. Bouzbib
- Preoperative TIPS prevents the development of post-operative acute-on-chronic liver failure in patients with high CLIF-C AD score  
M. Praktijnjo

#### 14.30-15.30 INDUSTRY SPONSORED SYMPOSIUM

#### 15.30-15.45 *Break*

# Baveno VII

CONSENSUS WORKSHOP  
PERSONALIZED CARE IN PORTAL HYPERTENSION

October 27-30, 2021

**VIRTUAL**



## SCIENTIFIC PROGRAMME

### FRIDAY OCTOBER 29 2021

#### 15.45-18.15 **SESSION 3**

#### **CLINICAL SETTINGS** (CONTINUED)

##### 15.45-16.45 **PART 2: Acute variceal bleeding**

*Chairpersons: V. Hernández-Gea (Barcelona, Spain), D. Thabut (Paris, France)*

*Panelists: A. Cárdenas (Barcelona, Spain), A. Escorsell (Barcelona, Spain),  
G. Han (Xi'an, China), X. Luo (Chengdu, China), D. Patch (London, United Kingdom),  
B. Procopet (Cluj-Napoca, Romania), M. Rudler (Paris, France)*

##### 15.45 **General Management and risk stratification**

*D. Patch (London, United Kingdom)*

##### 15.55 **Endoscopic management and gastric varices**

*A. Cárdenas (Barcelona, Spain)*

##### 16.05 **Preemptive TIPS and Refractory bleeding**

*M. Rudler (Paris, France)*

##### 16.15 **Management coagulation and PVT**

*B. Procopet (Cluj-Napoca, Romania)*

##### 16.25 **Proposed consensus statements**

*D. Thabut (Paris, France), V. Hernández-Gea (Barcelona, Spain)*

##### 16.45-17.00 **Break**

# Baveno VII

CONSENSUS WORKSHOP  
PERSONALIZED CARE IN PORTAL HYPERTENSION

October 27-30, 2021

**VIRTUAL**



## SCIENTIFIC PROGRAMME

### FRIDAY OCTOBER 29 2021

- 17.00-18.15 PART 3: Preventing further decompensation.**  
**Review of current evidence**  
*Chairpersons: G. Garcia-Tsao (New Haven, USA), T Reiberger (Vienna, Austria)*  
*Panelists: C. Bureau (Toulouse, France), G. D'Amico (Palermo, Italy), V. La Mura (Milan, Italy), S. Piano (Padua, Italy), P. Tandon (Edmonton, Canada), L. Turco (Bologna, Italy)*
- 17.00** Definition of further decompensation and re-compensation  
*G. Garcia-Tsao (New Haven, USA)*
- 17.10** Primary Prophylaxis in decompensated patients  
*L. Turco (Bologna, Italy)*
- 17.22** Secondary prophylaxis of variceal bleeding  
*V. La Mura (Milan, Italy)*
- 17.34** TIPS use for prevention of further decompensation  
*C. Bureau (Toulouse, France)*
- 17.44** The role of infections in further decompensation  
*S. Piano (Padua, Italy)*
- 17.52** Sarcopenia/Frailty in further decompensation  
*P. Tandon (Edmonton, Canada)*
- 18.00** Proposed consensus statements  
*G. Garcia-Tsao (New Haven, USA), T Reiberger (Vienna, Austria)*
- 18.10** Discussion

End of the Day

# Baveno VII

CONSENSUS WORKSHOP  
PERSONALIZED CARE IN PORTAL HYPERTENSION

October 27-30, 2021

**VIRTUAL**



## SCIENTIFIC PROGRAMME

### SATURDAY OCTOBER 30 2021

#### 14.00-15.00 INDUSTRY SPONSORED SYMPOSIUM

15.00-15.15 *Break*

#### SESSION 4

### VASCULAR LIVER DISORDERS

#### 15.15-16.30 PART 1: Splanchnic Vein Thrombosis

*Chairpersons: S. Sarin (New Delhi, India), D. Valla (Clichy, France)*

*Panelists: A. Baiges (Barcelona, Spain), M. Barrufet (Barcelona, Spain),*

*J.J. Kiladjian (Paris, France), A. Plessier (Clichy, France), M. Primignani (Milan, Italy),*

*A. Shukla (Mumbai, India), F. Turon (Barcelona, Spain)*

15.15 PVT. Anticoagulation vs Interventional radiology

*F. Turon (Barcelona, Spain), M. Barrufet (Barcelona, Spain)*

15.30 Staging of PVT. Recurrent thrombosis and prognostic factors for recurrence

*A. Plessier (Clichy, France)*

15.45 MNP and splanchnic Vein thrombosis. Diagnosis and management

*Lina Benajiba (Paris, France)*

16.00 Presentation of Consensus Statements

*D. Valla (Clichy, France), S. Sarin (New Delhi, India)*

16.30 Discussion

16.30-16.45 *Break*

# Baveno VII

CONSENSUS WORKSHOP  
PERSONALIZED CARE IN PORTAL HYPERTENSION

October 27-30, 2021

**VIRTUAL**



## SCIENTIFIC PROGRAMME

### SATURDAY OCTOBER 30 2021

#### 16.45-18.00 **PART 2: Other issues in vascular liver disorders**

*Chairpersons: A. de Gottardi (Lugano, Switzerland), P.E. Rautou (Paris, France)*

*Panelists: S. Murad (Rotterdam, The Netherlands), V. Paradis (Clichy, France), M. Senzolo (Padua, Italy), L. Tellez (Madrid, Spain)*

#### 16.55 Anticoagulation (Including DOACS) in cirrhotic and non-cirrhotic patients

*M. Senzolo (Padua, Italy)*

#### 17.10 PSVD/IPH: refining diagnostic criteria including histological criteria

*V. Paradis (Clichy, France), A. de Gottardi (Lugano, Switzerland)*

#### 17.25 Presentation of Consensus Statements

*A. de Gottardi (Lugano, Switzerland), P.E. Rautou (Paris, France)*

#### 17.50 Discussion

#### 18.00-18.15 *Break*

#### 18.15-18.45 **DIGITAL BAVENO VII MEETING WRAP UP**

*R. de Franchis (Milan, Italy)*

*G. Garcia-Tsao (New Haven, USA)*

*J. Bosch (Bern, Switzerland)*

**End of the Workshop**

# Baveno VII

CONSENSUS WORKSHOP  
PERSONALIZED CARE IN PORTAL HYPERTENSION

October 27-30, 2021

**VIRTUAL**



## PEDIATRIC RESEARCH WORKSHOP

### BAVENO VII PEDIATRIC RESEARCH WORKSHOP

**SUNDAY OCTOBER 31, 2021**

**Primary Prophylaxis of Variceal Hemorrhage,  
Complexities in the Development  
of Evidence-Based Approaches in Pediatrics**

**15.00-17.05\*** Background and Rationale for Investigation

**15.00** Introduction and goals

B. Shneider (*Houston*)

**15.05** Morbidity and Mortality of First Variceal Hemorrhage

J.P. Molleston (*Indianapolis*)

**15.25** Experiences in Endoscopic Primary Prophylaxis

M. Duché (*Paris*)

**15.45** Rationale for Primary Prophylaxis in Adults

R. de Franchis (*Milan*)

**16.05** Complexity of a Randomized Clinical Trial in Pediatrics

S. Ling (*Toronto*)

**16.25** International Registries in Pediatric Liver Diseases - The PSC Experience

M. Deneau (*Salt Lake City*)

**16.45** Open Discussion - Q&A^

**17.05-17.20** Break

# Baveno VII

CONSENSUS WORKSHOP  
PERSONALIZED CARE IN PORTAL HYPERTENSION

October 27-30, 2021

VIRTUAL



## PEDIATRIC RESEARCH WORKSHOP

### 17.20-19.30 Research Plan Discussion

17.20 Introduction of a Pediatric Portal Hypertension Registry  
B. Shneider (Houston)

17.30 Presentation of the First Variceal Hemorrhage Database  
J. Pimenta (Belo Horizonte)

17.45 Presentation of the Primary Prophylaxis Database  
T. Grammatikopoulos (London)

18.00 Primary and Pre-primary Prophylaxis of Variceal Hemorrhage  
with the MesoRex Bypass and a MesoRex Bypass Registry  
R. Superina (Chicago)

18.15 Registry Discussion<sup>^</sup>

19.00 Concluding Remarks  
J. Bosch<sup>^</sup> (Berne)

19.15 Plans Forward  
B. Shneider <sup>^</sup> (Houston)

\* times CET <sup>^</sup> all talks are pre-recorded with the exception of the ones marked by <sup>^</sup> which will be as a panel discussion with on-line questions via a chat-type function

## FACULTY

Jaime Bosch - Bern, Switzerland

Roberto de Franchis - Milan, Italy

Mark Deneau - Salt Lake City, USA

Mathieu Duché - Paris, France

Tassos Grammatikopoulos - London, United Kingdom

Simon C. Ling - Toronto, Canada

Jean P. Molleston - Indianapolis, USA

Júlio R. Pimenta - Belo Horizonte, Brazil

Benjamin L. Shneider - Houston, USA

Riccardo Superina - Chicago, USA

# Bavendo VII

CONSENSUS WORKSHOP  
PERSONALIZED CARE IN PORTAL HYPERTENSION

October 27-30, 2021



## INDUSTRY SPONSORED SYMPOSIUM

### FRIDAY OCTOBER 29 2021

#### 14.30-15.30 INDUSTRY SPONSORED SYMPOSIUM

## CONTROLLED EXPANSION TIPS. WHERE ARE WE?

Historic overview and a future outlook.

## More than 20 years of GORE® VIATORR® TIPS Endoprosthesis

*Moderation: T. Reiberger (Vienna, Austria)*

- 14.30** The history of the TIPS procedure.  
Experience with the GORE® VIATORR® TIPS Endoprosthesis  
*J. Bosch (Bern, Switzerland)*
- 14.45** Pre-emptive TIPS in patients with high risk acute variceal  
bleeding  
*J.C. Garcia-Pagán (Barcelona, Spain)*
- 15.00** The future of small TIPS  
*J. Trebicka (Frankfurt, Germany)*
- 15.15** Conclusion by the moderator and discussion
- 15.30** Closing



# Bavendo VII

CONSENSUS WORKSHOP  
PERSONALIZED CARE IN PORTAL HYPERTENSION

October 27-30, 2021



## INDUSTRY SPONSORED SYMPOSIUM

### SATURDAY OCTOBER 30 2021

#### 14.00-15.00 INDUSTRY SPONSORED SYMPOSIUM

### **EUS-guided portal pressure measurement: expanding the horizon in portal hypertension assessment**

**14.00** Welcome

J.C. García-Pagán (*Barcelona, Spain*)

**14.05** Portal hypertension assessment - Future Potential

W. Laleman (*Leuven, Belgium*)

**14.25** EUS-guided portal pressure measurement - Early clinical experience

S. van der Merwe (*Leuven, Belgium*)

**14.45** Q&A discussion

**14.58-15.00** Close

# Baveno VII

CONSENSUS WORKSHOP  
PERSONALIZED CARE IN PORTAL HYPERTENSION

October 27-30, 2021

**VIRTUAL**



## CME

The BAVENO VII VIRTUAL CONSENSUS WORKSHOP “PERSONALIZED CARE IN PORTAL HYPERTENSION”, 27/10/2021-31/10/2021 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 15 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credit to AMA credit can be found at [www.ama-assn.org/education/earn-credit-participation-international-activities](http://www.ama-assn.org/education/earn-credit-participation-international-activities).

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

**In order to claim CME credits it is mandatory to fill in the CME questionnaire and the EACCME® participant's evaluation form at the end of the Workshop. The fulfillment of the documents will be possible on the Baveno 7 platform from the end of the Workshop on Saturday, October 30 until Tuesday November 2 at pm CET time. No delays in the fulfillment will be accepted.**

Certificates of granted credits will be sent by e-mail after the Workshop to those who have attended the Workshop and filled in all relevant documents.

# Baveno VII

CONSENSUS WORKSHOP  
PERSONALIZED CARE IN PORTAL HYPERTENSION

October 27-30, 2021

**VIRTUAL**



## REGISTRATION FEE

(22% VAT included- VAT is quoted according the actual rate in force. All rices will updated in case of legal changes in the applicable rates)

● EARLY BIRD REGISTRATION - till September 10, 2021	€ 450,00
● FULL REGISTRATION - after September 10, 2021	€ 550,00
● PEDIATRIC RESEARCH WORKSHOP**	€ 75,00
● YOUNG INVESTIGATOR EARLY BIRD FEE* - till September 10, 2021	€ 150,00
● YOUNG INVESTIGATOR FULL REGISTRATION - after September 10, 2021	€ 200,00
● YOUNG INVESTIGATOR PEDIATRIC RESEARCH WORKSHOP**	€ 25,00
● YOUNG INVESTIGATOR * "EMERGING COUNTRIES" ***	€ 100,00

\* Young investigators must be under 35 years old and still in training at the time of the Workshop. Proof of age and training status is mandatory

\*\* Registration in the Baveno VII Workshop is mandatory to register for the Pediatric Research Workshop

\*\*\* Emerging Countries are those defined as low-income and lower-middle income economies as determined by the World Bank

(Source: World Bank, low-income and lower-middle income countries current 2020 fiscal year - <http://data.worldbank.org/about/country-and-lending-groups>)

The Registration fee includes:

- Admission to scientific sessions
- Admission to the exhibition area
- Attendance Certificate

## HOW TO REGISTER IN THE WORKSHOP

Registration can be made online through the [www.baveno7.com](http://www.baveno7.com) website and paid by credit card.

# Baveno VII

CONSENSUS WORKSHOP  
PERSONALIZED CARE IN PORTAL HYPERTENSION

October 27-30, 2021

**VIRTUAL**



WITH THE SUPPORT OF



echosens

